Aim. To optimize chronic heart failure (CHF) pharmacotherapy, basing on endothelin (ET) system activity, functional and cardio-hemodynamic parameters, and their dynamics in beta-adrenoblocker nebivolol therapy. Material and methods. The study included 52
L. I. Olbinskaya, Yu. I. Naymann
doaj
Early Detection of Nebivolol-Induced Hepatotoxicity. [PDF]
Torunova AM, Kireeva VV, Kurganskii IS.
europepmc +1 more source
Protective effects of beta-blockers against anthracycline- and trastuzumab-related cardiotoxicity: a systematic review based on conventional and Bayesian network meta-analysis. [PDF]
Jiang S, Gao G.
europepmc +1 more source
Comparative Effectiveness and Outcomes of Nebivolol Versus Other Beta Blockers in Patients With Hypertension: A Multicenter Cohort Study. [PDF]
Chang YC +4 more
europepmc +1 more source
The Effects of Nebivolol on Moderate Traumatic Brain Injury in a Rat Model: Implications for Pediatric Neuroprotection. [PDF]
Esfahani MAA +5 more
europepmc +1 more source
Nebivolol prevents exhausted T cells and enhances cytotoxicity against MCF-7 breast cancer cells in a β2-adrenergic receptor-dependent manner. [PDF]
Hajiaghayi M +5 more
europepmc +1 more source
Epicardial vasospasm and concomitant ventricular tachycardia treated with Beta-1-specific Beta-blockade: a case series in support of nebivolol. [PDF]
Miner SA +5 more
europepmc +1 more source
Potentiating anti-inflammatory and antioxidant effects in vitro: the combined action of zofenoprilat and nebivolol. [PDF]
Maceroni E +8 more
europepmc +1 more source
Beyond the Heart: The Neuroprotective Potential of Nebivolol in Acute Myocardial Infarction. [PDF]
Mercanoglu G +4 more
europepmc +1 more source

